The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on CVS Health (CVS – Research Report), with a price target of

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. During the quarter,

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide range of health solutions in the United States. With offerings that span pharmacy benefit management,

In 2018, CVS acquired the insurer, Aetna, and in 2007, the company acquired pharmacy services provider Caremark Rx. Adding Signify Health to the mix presents an opportunity for CVS to drive ...

The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, CVS's Health Care Benefits segment operates as one of the largest diversified health care benefits providers, serving more than 35 million people. This segment accounts for approximately 30% of the consolidated revenue.

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

A GoLocal investigation explores how CVS and its then-President Helena Foulkes often told one story about opioids while the company profited, and she made tens of millions in salary, stock incentives,

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $65.0 for CVS Health over the last 3 months.

CVS Health's poor 2024 performance was driven by ... PBMs and MA plans are core to the CVS Caremark and Aetna insurance segments. But will the rhetoric stick? PBMs are an easy target.

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The